Anti-Inflammatory, Metabolic, and Cardiovascular Effects

How this citrus flavonoid found in grapefruit and oranges reduces inflammation, improves lipid profiles, and protects against metabolic syndrome

Naringenin is the principal flavonoid in grapefruit — the compound responsible for its characteristic bitter edge — and is also found in oranges, tangerines, tomatoes, and cherries. It belongs to the flavanone subclass of polyphenols and has been studied for its ability to quiet inflammation through NF-κB suppression, activate the body's antioxidant defenses via Nrf2, lower LDL cholesterol and triglycerides, improve insulin sensitivity, and protect blood vessels from atherosclerotic damage [1][2][3]. Most of the robust evidence comes from preclinical and animal studies, with emerging clinical data in people with hypercholesterolemia and metabolic syndrome. People taking certain medications should be aware of grapefruit's well-known interaction with liver enzymes before regularly consuming large quantities.

How Naringenin Works

Naringenin belongs to the flavanone subclass of flavonoids — structurally distinct from flavonols like quercetin and kaempferol by the absence of a double bond in the C ring, which gives it a slightly different receptor-binding profile. Despite this structural distinction, naringenin engages many of the same core signaling pathways as other well-studied flavonoids, while also activating metabolic pathways of particular relevance to lipid regulation and insulin signaling.

Anti-Inflammatory Mechanisms: NF-κB and Nrf2

Naringenin inhibits NF-κB (nuclear factor kappa B), the transcription factor that functions as a master switch for pro-inflammatory gene expression. By blocking IκB kinase (IKK) and preventing IκB-α degradation, naringenin keeps NF-κB sequestered in the cytoplasm and unable to drive production of TNF-α, IL-1β, IL-6, and COX-2 [5]. It also downregulates Th1 cytokines — the inflammatory signaling molecules that drive autoimmune-type activation — and inhibits xanthine oxidase, an enzyme that generates reactive oxygen species as a byproduct of uric acid metabolism.

Simultaneously, naringenin activates Nrf2, the transcription factor that induces the cell's own antioxidant enzymes: superoxide dismutase (SOD), catalase, glutathione peroxidase, and glutathione S-transferase [5]. This dual action — suppressing inflammatory signals while boosting endogenous antioxidant capacity — is a pattern shared with other plant polyphenols and likely explains the consistency of effect across diverse tissue models.

Metabolic Regulation: AMPK and PPARα

What distinguishes naringenin from many other flavonoids is its pronounced activity on metabolic signaling pathways. Naringenin activates AMPK (AMP-activated protein kinase), often called the cellular energy sensor, which responds to low energy states by shifting metabolism toward fat burning and away from fat storage. AMPK activation inhibits fatty acid synthesis (by phosphorylating and inactivating acetyl-CoA carboxylase) and promotes fatty acid oxidation in the liver [3].

Naringenin also activates PPARα (peroxisome proliferator-activated receptor alpha), a nuclear receptor that controls genes involved in fat transport, beta-oxidation, and ketone body production. PPARα activation in the liver reduces hepatic triglyceride accumulation, decreases VLDL production, and lowers circulating triglycerides. Together, AMPK and PPARα activation explain why naringenin shows consistent lipid-lowering effects across animal studies [3].

Lipid Metabolism: Multiple Mechanisms

The 2022 update by Yang and colleagues identified several distinct mechanisms by which naringenin (and its glycoside naringin) improve lipid profiles [4]:

LDL clearance: Naringenin suppresses PCSK9, the protein that degrades LDL receptors on liver cells. Lower PCSK9 means more LDL receptors stay active and remove more LDL-cholesterol from circulation — the same principle exploited by the newest class of cholesterol-lowering drugs.
Bile acid conversion: It promotes conversion of hepatic cholesterol to bile acids, reducing intracellular cholesterol load.
Dietary fat absorption: Naringin inhibits pancreatic lipase, the enzyme that breaks down dietary triglycerides in the small intestine, modestly reducing fat absorption from meals.
Hepatic steatosis prevention: By promoting fat oxidation and inhibiting fat synthesis simultaneously, naringenin protects against non-alcoholic fatty liver disease in animal models.

Cardiovascular Protection

Naringenin protects blood vessels through multiple mechanisms that overlap with its anti-inflammatory and metabolic effects. In endothelial cells, it preserves nitric oxide synthase (eNOS) function, maintaining healthy vasodilation and reducing the expression of adhesion molecules (VCAM-1, ICAM-1) that recruit immune cells to vessel walls — the first step in atherosclerotic plaque formation [2]. It reduces oxidized LDL-induced endothelial damage and inhibits foam cell formation, the process by which macrophages loaded with oxidized cholesterol accumulate in artery walls.

The review by Moghaddam and colleagues documented protective effects across several cardiovascular conditions including diabetic cardiomyopathy, ischemia-reperfusion injury, and diet-induced atherosclerosis, consistently through antioxidant and anti-inflammatory mechanisms [2].

Food Sources and Concentrations

Naringenin content in food is most concentrated in citrus:

Grapefruit — the richest source; naringenin accounts for the bitter taste. Both flesh and juice contain meaningful amounts, with one grapefruit providing roughly 40–70 mg of naringenin/naringin combined.
Oranges and tangerines — lower concentrations than grapefruit but still significant contributors for regular consumers
Tomatoes — naringenin is present in tomato skin at modest concentrations
Cherries — present at lower levels
Bergamot — a citrus fruit used in supplements and Earl Grey tea; particularly high in flavanones including naringenin derivatives

Cooking and processing affect content variably. Grapefruit juice retains naringenin well. Fermentation (as in kvass or some fermented citrus preparations) increases bioavailability by breaking glycoside bonds.

Supplementation

Concentrated naringenin supplements are available, typically 250–500 mg per capsule, as isolated naringenin or as bergamot extract, which is a flavanone-rich citrus derivative studied specifically in clinical trials for lipid lowering. Clinical studies that have demonstrated effects used doses in the 600–800 μM/day range, primarily in individuals with hypercholesterolemia [1].

Drug interaction note: Naringenin and its glycoside naringin inhibit CYP3A4 and CYP1A2 — cytochrome P450 liver enzymes responsible for metabolizing a wide range of medications. This is the well-known grapefruit-drug interaction. Affected medications include certain statins, calcium channel blockers, immunosuppressants, anticoagulants, and many others. Anyone taking medications should check for grapefruit interactions before adding high-dose naringenin supplements or consuming large quantities of grapefruit regularly. Occasional grapefruit consumption is generally fine; consistent daily intake of grapefruit or high-dose supplements is where interactions become clinically significant.

See our quercetin page for a related flavonoid with strong anti-inflammatory evidence and a well-developed clinical base. The hesperidin page covers another citrus flavanone with particularly strong venous circulation evidence. The bergamot page addresses the most clinically studied citrus flavanone preparation for lipid lowering.

Evidence Review

Clinical Evidence: Promising but Limited

The most clinically relevant synthesis is the 2019 review by Salehi and colleagues (PMID 30634637), published in Pharmaceuticals (Basel), which catalogued human clinical trials involving naringenin and naringin. The review identified that most human data involves cardiovascular endpoints in compromised populations — specifically individuals with hypercholesterolemia and overweight — rather than healthy volunteers. Doses in human trials ranged from approximately 600 to 800 μM/day.

Key clinical findings documented in the review include arterial stiffness improvements following grapefruit juice consumption (containing naringenin glycoside) in postmenopausal women, alongside favorable changes in inflammatory markers in small trials. The reviewers concluded that naringenin's ability to improve endothelial function "has been well-established," but emphasized that pharmacokinetic characterization in humans remains incomplete and that larger, controlled trials are needed to establish dose-response relationships and clinical efficacy thresholds.

Limitation: The clinical trial literature on naringenin specifically (as opposed to grapefruit juice, naringin, or bergamot extract) is sparse. Most human data uses mixed citrus preparations rather than isolated naringenin, making it difficult to attribute effects exclusively to this compound. Effect sizes in existing trials are generally modest and many studies are small (under 50 participants).

Cardiovascular Effects: Preclinical Evidence Base

Moghaddam and colleagues (PMID 32910944), published in European Journal of Pharmacology in 2020, conducted a detailed preclinical review of naringenin and naringin's cardiovascular effects across animal and cell-culture models. The review organized evidence by mechanism and condition type:

Antioxidant activity: Across multiple oxidative stress models, naringenin consistently enhanced activity of endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase) and reduced malondialdehyde (MDA), a marker of lipid peroxidation. Effect sizes in rodent models were substantial — 40–60% reductions in oxidative markers at relevant doses.

Anti-inflammatory activity: Naringenin reduced circulating TNF-α, IL-6, and IL-1β in models of diet-induced cardiovascular disease. The anti-inflammatory effects were particularly pronounced in models of diabetic cardiomyopathy, where chronic low-grade inflammation drives cardiac fibrosis and dysfunction.

Ischemia-reperfusion protection: In models of cardiac ischemia (blocked blood flow followed by reperfusion), naringenin pretreatment reduced infarct size and preserved cardiac function by limiting oxidative burst during reperfusion and reducing cardiomyocyte apoptosis.

Limitation: All primary studies in this review are animal or cell-culture models. The cardiovascular protection in ischemia models, while mechanistically compelling, has not been tested in human trials. Translation from rodent cardiac physiology to human outcomes is uncertain.

Metabolic Syndrome: AMPK and PPARα Mechanisms

Massaro and colleagues (PMID 36043734), published in Endocrine, Metabolic and Immune Disorders - Drug Targets in 2023, examined the mechanistic basis of naringenin's effects on components of metabolic syndrome — a cluster of conditions including abdominal obesity, elevated triglycerides, low HDL, high blood pressure, and impaired fasting glucose.

The review documented that naringenin and naringin consistently improved multiple metabolic syndrome parameters in animal models:

Obesity: Reduced body weight gain and visceral fat accumulation through AMPK activation, which shifts energy metabolism toward fatty acid oxidation
Dyslipidemia: Reduced total cholesterol, LDL, and triglycerides by 20–40% in hyperlipidemic animal models; increased HDL in most studies
Insulin resistance: Improved insulin signaling through IRS-1/PI3K/Akt pathway upregulation and reduced hepatic gluconeogenesis
Hepatic steatosis: Prevented accumulation of liver triglycerides through combined PPARα activation (increasing fat oxidation) and SREPB-1c suppression (decreasing fat synthesis)

The authors noted that while the preclinical evidence is mechanistically well-supported, clinical application has been limited by bioavailability challenges and the absence of adequately powered human trials. They identified AMPK and PPARα as the most pharmacologically tractable targets for clinical translation.

Lipid Metabolism: PCSK9, Bile Acids, and Absorption

Yang and colleagues (PMID 35189328), published in the Journal of Nutritional Biochemistry in 2022, provided the most mechanistically detailed account of how citrus flavanones affect lipid metabolism. The review highlighted PCSK9 suppression as a particularly important mechanism: PCSK9 is a protein that marks LDL receptors for degradation, reducing the liver's capacity to clear LDL from blood. Naringenin's suppression of PCSK9 expression in hepatocytes — confirmed in cell culture models — represents a mechanism convergent with that of a major pharmaceutical drug class (PCSK9 inhibitors), though at a much lower potency.

The review also quantified the lipase inhibition effect: naringin reduced pancreatic lipase activity by approximately 30–40% in vitro at physiologically relevant concentrations, suggesting meaningful reduction in dietary fat hydrolysis and absorption. This effect would be additive to the hepatic lipid-lowering mechanisms.

Population variability was an important theme: in individuals with obesity and diabetes, naringenin's lipid effects were less consistent than in lean or mildly hyperlipidemic models, possibly due to differences in gut microbiota composition (which affects naringenin bioactivation), hepatic insulin resistance (which alters PPARα responsiveness), and baseline LDL receptor expression.

Anti-inflammatory and Neuroprotective Mechanisms

Solanki and colleagues (PMID 39076091), published in Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry in 2025, provided the most recent synthesis of naringenin's immunomodulatory and neuroprotective evidence. The review confirmed NF-κB inhibition and Nrf2 activation as primary mechanisms, with downstream reduction of superoxide radicals and lipid peroxidation.

For neuroprotection, the review documented:

Inhibition of neuroinflammatory signaling in microglial cells (the brain's resident immune cells) — a mechanism relevant to neurodegenerative disease progression
Reduction of oxidative stress in neuronal cells through Nrf2-mediated antioxidant enzyme induction
Modulation of Th1/Th2 balance toward reduced inflammatory activation

The authors identified naringenin's main limitation explicitly: "the principal obstacle to naringenin's adoption as a therapeutic agent remains the dearth of in vivo data," and recommended development of improved delivery formulations to overcome the bioavailability constraints that limit plasma concentrations after oral dosing.

Bioavailability note: Naringenin, like most flavanones, is absorbed as its glycoside (naringin) in the gut, where the sugar moiety is cleaved by intestinal bacteria before the aglycone is absorbed. Oral bioavailability studies suggest peak plasma concentrations reach 0.5–5 μM after typical dietary exposure, with meaningful interindividual variability based on gut microbiome composition. These concentrations are lower than the effective concentrations used in many in vitro studies, though tissue concentrations at target sites may be higher. Formulations such as phospholipid complexes and nanoparticles increase bioavailability several-fold in rodent models.

Overall Evidence Assessment

Naringenin has a well-developed mechanistic profile — anti-inflammatory via NF-κB/Nrf2, lipid-lowering via AMPK/PPARα/PCSK9, cardiovascular-protective via endothelial and antioxidant mechanisms — with consistent animal model evidence. Human clinical data is limited in quantity and scope, focused primarily on lipid endpoints in high-risk populations. The compound's presence in ordinary dietary sources (grapefruit, oranges) means that food-based exposure is practical and safe, with the well-characterized caveat around CYP3A4-mediated drug interactions. The most evidence-grounded practical takeaway is that regular citrus consumption — particularly grapefruit for those not on affected medications — contributes meaningful flavanone intake alongside dietary fiber, vitamin C, and other compounds with complementary cardiovascular and metabolic effects.

References

The Therapeutic Potential of Naringenin: A Review of Clinical TrialsSalehi B, Tsouh Fokou PV, Sharifi-Rad M, Zucca P, Pezzani R, Martins N, Sharifi-Rad J. Pharmaceuticals (Basel), 2019. PubMed 30634637 →
Naringenin and naringin in cardiovascular disease prevention: A preclinical reviewMoghaddam RH, Samimi Z, Moradi SZ, Little PJ, Xu S, Farzaei MH. European Journal of Pharmacology, 2020. PubMed 32910944 →
The Potential Role of Naringin and Naringenin as Nutraceuticals Against Metabolic SyndromeMassaro L, Raguzzini A, Aiello P, Villaño Valencia D. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2023. PubMed 36043734 →
Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: An update on bioavailability, pharmacokinetics, and mechanismsYang Y, Trevethan M, Wang S, Zhao L. Journal of Nutritional Biochemistry, 2022. PubMed 35189328 →
Naringenin: A Promising Immunomodulator for Anti-inflammatory, Neuroprotective and Anti-cancer ApplicationsSolanki S, Vig H, Khatri N, Singh BP, Khan MS, Devgun M, Wal P, Wal A. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2025. PubMed 39076091 →